Safety and Efficacy of Etoricoxib 30 mg Versus Celecoxib 200 mg in Korean Participants With Osteoarthritis
Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to establish that etoricoxib 30 mg is safe and not inferior
to celecoxib 200 mg in the treatment of the signs and symptoms of osteoarthritis in Korean
patients. Given that the efficacy of etoricoxib vs. placebo in the treatment of
osteoarthritis has been established, and that prescription drugs, such as celecoxib, are
available for the treatment of pain associated with osteoarthritis in Korea, it would be
inappropriate to subject patients with a flare of osteoarthritic pain to the placebo
treatment for 12 weeks, and thus the study is designed as an active-comparator study.